Stock listing

BIVA:ACAD ACADIA Pharmaceuticals Inc. Acciones

Mexican listing (BIVA) of ACADIA Pharmaceuticals Inc. · home listing NASDAQ:ACAD

Follow ACADIA Pharmaceuticals Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ACAD

$19.80 USD +0.68 (+3.6%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ACAD

Since Jul 6, 2026 -23.2% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$19.11 – $19.84 USDOct 19, 2026
Volume
1.30M sharesOct 19, 2026
Market value
$3.41B USDAt the close on Oct 19, 2026 · price × 172.3M shares outstanding
ACADIA Pharmaceuticals Inc. logo
Ticker
BIVA:ACAD
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
BIVA
Currency
MXN

What changed lately

Calls

Replays

  • ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 2026 Earnings Call

    Tue, Aug 04, 2026 · 4:30 PM ET

    Watch Transcript

  • ACADIA Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Call

    Wed, May 06, 2026 · 4:30 PM ET

    Watch Transcript

  • ACADIA Pharmaceuticals (NASDAQ:ACAD) Q4 2025 Earnings Call

    Wed, Feb 25, 2026 · 4:30 PM ET

    Watch Transcript

Latest news

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

Sep 28, 2026

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)

Sep 24, 2026

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

Aug 24, 2026

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

Aug 4, 2026

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference

Jul 30, 2026

Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis

Jul 20, 2026

Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026

Jul 15, 2026

Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer

Jul 6, 2026

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

Jun 26, 2026

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

May 6, 2026

All ACADIA Pharmaceuticals Inc. news

Decks

ACADIA Pharmaceuticals Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
26 in the last 12 months · 193 in all · newest Sep 28, 2026 · oldest 2019
Calls
26 calls with a replay · 26 with a transcript · latest Aug 4, 2026
Decks
30 decks · latest Sep 24, 2026

Where ACADIA Pharmaceuticals Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ACAD · Home listingNASDAQUnited StatesUSD
gettex:DR6gettexGermanyEUR
Tradegate:DR6TradegateGermanyEUR
BMV:ACADBMVMexicoMXN
LS Exchange:603035LS ExchangeGermanyEUR
Lang & Schwarz:603035Lang & SchwarzGermanyEUR
Frankfurt:DR6FrankfurtGermanyEUR
BIVA:ACAD · This pageBIVAMexicoMXN
BOATS:ACADBOATSUnited StatesUSD
LSE:0A4WLSEUnited KingdomUSD
Dusseldorf:DR6DusseldorfGermanyEUR
Munich:DR6MunichGermanyEUR
Stuttgart:DR6StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about ACADIA Pharmaceuticals Inc.